737 related articles for article (PubMed ID: 19262226)
21. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
[TBL] [Abstract][Full Text] [Related]
22. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Smebye ML; Iversen EK; Høieggen A; Flaa A; Os I; Kjeldsen SE; Olsen MH; Chattopadhyay A; Hille DA; Lyle PA; Devereux RB; Dahlöf B
Am J Cardiol; 2007 Sep; 100(5):855-9. PubMed ID: 17719333
[TBL] [Abstract][Full Text] [Related]
23. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
[TBL] [Abstract][Full Text] [Related]
24. Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
Fossum E; Olsen MH; Høieggen A; Wachtell K; Reims HM; Ibsen H; Julius S; Kjeldsen SE
J Hum Hypertens; 2004 Jun; 18(6):375-80. PubMed ID: 15057253
[TBL] [Abstract][Full Text] [Related]
25. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
26. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Dahlöf B; Burke TA; Krobot K; Carides GW; Edelman JM; Devereux RB; Diener HC
J Hum Hypertens; 2004 Jun; 18(6):367-73. PubMed ID: 15029217
[TBL] [Abstract][Full Text] [Related]
27. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Fossum E; Moan A; Kjeldsen SE; Devereux RB; Julius S; Snapinn SM; Edelman JM; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Dahlöf B;
J Am Coll Cardiol; 2005 Sep; 46(5):770-5. PubMed ID: 16139123
[TBL] [Abstract][Full Text] [Related]
28. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
29. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
[TBL] [Abstract][Full Text] [Related]
30. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
de Simone G; Wachtell K; Palmieri V; Hille DA; Beevers G; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Julius S; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Devereux RB
Circulation; 2005 Apr; 111(15):1924-31. PubMed ID: 15837945
[TBL] [Abstract][Full Text] [Related]
31. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of hypertension in patients with left ventricular hypertrophy].
Omvik P; Bratland B; Gerhardsen G; Gisholt K; Risanger T; Smedsrud T; Kjeldsen SE
Tidsskr Nor Laegeforen; 2004 Mar; 124(6):788-91. PubMed ID: 15039810
[TBL] [Abstract][Full Text] [Related]
33. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
35. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B; Gleim G; Panish J
Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
[TBL] [Abstract][Full Text] [Related]
36. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Ariansen I; Reims HM; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Kjeldsen SE; Dahlöf B; Wachtell K
Blood Press; 2012 Feb; 21(1):6-11. PubMed ID: 22070095
[TBL] [Abstract][Full Text] [Related]
37. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
[TBL] [Abstract][Full Text] [Related]
38. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
Wachtell K; Palmieri V; Gerdts E; Bella JN; Aurigemma GP; Papademetriou V; Dahlöf B; Aalto T; Ibsen H; Rokkedal JE; Devereux RB
Am J Cardiol; 2010 Oct; 106(7):999-1005. PubMed ID: 20854964
[TBL] [Abstract][Full Text] [Related]
40. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Carr AA; Kowey PR; Devereux RB; Brenner BM; Dahlöf B; Ibsen H; Lindholm LH; Lyle PA; Snapinn SM; Zhang Z; Edelman JM; Shahinfar S
Am J Cardiol; 2005 Dec; 96(11):1530-6. PubMed ID: 16310435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]